Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024Accesswire • 05/31/24
Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 CongressAccesswire • 05/14/24
Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors EventAccesswire • 05/07/24
Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate UpdateAccesswire • 05/07/24
All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to BuyZacks Investment Research • 04/05/24
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line DataAccesswire • 03/26/24
Wall Street Analysts Think Protagonist Therapeutics (PTGX) Could Surge 48.38%: Read This Before Placing a BetZacks Investment Research • 03/18/24
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with TakedaAccesswire • 03/18/24
Earnings Estimates Moving Higher for Protagonist Therapeutics (PTGX): Time to Buy?Zacks Investment Research • 03/01/24
Are You Looking for a Top Momentum Pick? Why Protagonist Therapeutics (PTGX) is a Great ChoiceZacks Investment Research • 03/01/24
Protagonist Therapeutics (PTGX) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 03/01/24
Wall Street Analysts Believe Protagonist Therapeutics (PTGX) Could Rally 37.16%: Here's is How to TradeZacks Investment Research • 03/01/24
Recent Price Trend in Protagonist Therapeutics (PTGX) is Your Friend, Here's WhyZacks Investment Research • 03/01/24
Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateAccesswire • 02/27/24
New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia VeraAccesswire • 02/21/24
New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis StudyAccesswire • 02/07/24
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology AssetAccesswire • 01/31/24
Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024Accesswire • 01/29/24
Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceAccesswire • 01/03/24
Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative ColitisAccesswire • 12/13/23